4 news items
AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
ABBV
31 May 24
."
Use of risankizumab in UC is not approved in the European Union, and its safety and efficacy remain under evaluation
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
AAL
ABBV
ACI
21 Apr 24
(NYSE:WHR), Western Union Company (NYSE:WU
What's Going On AbbVie Stock On Friday?
ABBV
12 Apr 24
. and Aquipta in the European Union (EU), is approved in 45 countries.
In 2023, Qulipta generated sales of $408 million, with fourth-quarter
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
ABBV
12 Apr 24
. and AQUIPTA® in the European Union (EU), is approved in 45 countries. It is an oral calcitonin gene-related peptide (CGRP) receptor
- Prev
- 1
- Next